Search

Your search keyword '"Concin, Nicole"' showing total 502 results
Start Over Author "Concin, Nicole"
502 results on '"Concin, Nicole"'

1. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

Author

Arends, Christopher Maximilian, Kopp, Klara, Hablesreiter, Raphael, Estrada, Natalia, Christen, Friederike, Moll, Ute Martha, Zeillinger, Robert, Schmitt, Wolfgang Daniel, Sehouli, Jalid, Kulbe, Hagen, Fleischmann, Maximilian, Ray-Coquard, Isabelle, Zeimet, Alain, Raspagliesi, Francesco, Zamagni, Claudio, Vergote, Ignace, Lorusso, Domenica, Concin, Nicole, Bullinger, Lars, Braicu, Elena Ioana, and Damm, Frederik

Published
2024
Full Text
View/download PDF

3. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

Author

Arends, Christopher Maximilian, Kopp, Klara, Hablesreiter, Raphael, Estrada, Natalia, Christen, Friederike, Moll, Ute Martha, Zeillinger, Robert, Schmitt, Wolfgang Daniel, Sehouli, Jalid, Kulbe, Hagen, Fleischmann, Maximilian, Ray-Coquard, Isabelle, Zeimet, Alain, Raspagliesi, Francesco, Zamagni, Claudio, Vergote, Ignace, Lorusso, Domenica, Concin, Nicole, Bullinger, Lars, Braicu, Elena Ioana, and Damm, Frederik

Published
2024
Full Text
View/download PDF

4. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer—a study of the OVCAD consortium

Author

Heinzl, Nicole, Maritschnegg, Elisabeth, Koziel, Katarzyna, Schilhart-Wallisch, Christine, Heinze, Georg, Yang, Wei-Lei, Bast, Robert C., Sehouli, Jalid, Braicu, Elena I., Vergote, Ignace, Van Gorp, Toon, Mahner, Sven, Paspalj, Valentina, Grimm, Christoph, Obermayr, Eva, Schuster, Eva, Holzer, Barbara, Rousseau, Frederic, Schymkowitz, Joost, Concin, Nicole, and Zeillinger, Robert

Published
2023
Full Text
View/download PDF

6. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

Author

Harter, Philipp, Bogner, Gerhard, Chiva, Luis, Cibula, David, Concin, Nicole, Fotopoulou, Christina, Gonzalez-Martin, Antonio, Guyon, Frederic, Heinzelmann-Schwarz, Viola, Kridelka, Frederic, Mahner, Sven, Marmé, Frederik, Marth, Christian, Morice, Philippe, Novák, Zoltán, Papadia, Andrea, Ray-Coquard, Isabelle, Redecha, Mikuláš, Redondo, Andres, Schwameis, Richard, Sehouli, Jalid, Undurraga, Manuela, Van Gorp, Toon, and Vergote, Ignace

Published
2024
Full Text
View/download PDF

7. Lymph node staging in grade 1–2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?

Author

Bizzarri, Nicolò, Imterat, Majdi, Fruscio, Robert, Giannarelli, Diana, Perrone, Anna Myriam, Mancari, Rosanna, Traut, Alexander, Rosati, Andrea, du Bois, Andreas, Ferrari, Debora, De Iaco, Pierandrea, Ergasti, Raffaella, Ataseven, Beyhan, Bianchi, Tommaso, Di Stanislao, Marco, Perri, Maria Teresa, Heitz, Florian, Concin, Nicole, Fanfani, Francesco, Vizza, Enrico, Scambia, Giovanni, Harter, Philipp, and Fagotti, Anna

Published
2023
Full Text
View/download PDF

9. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres

Author

Schwameis, Richard, Fanfani, Francesco, Ebner, Christoph, Zimmermann, Naomi, Peters, Inge, Nero, Camilla, Marth, Christian, Ristl, Robin, Leitner, Katharina, Grimm, Christoph, Oberndorfer, Felicitas, Capasso, Ilaria, Zeimet, Alain G., Polterauer, Stephan, Scambia, Giovanni, Fagotti, Anna, and Concin, Nicole

Published
2023
Full Text
View/download PDF

11. Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer

Author

Vanderstichele, Adriaan, Busschaert, Pieter, Landolfo, Chiara, Olbrecht, Siel, Coosemans, An, Froyman, Wouter, Loverix, Liselore, Concin, Nicole, Braicu, Elena Ioana, Wimberger, Pauline, Van Nieuwenhuysen, Els, Han, Sileny N., Van Gorp, Toon, Venken, Tom, Heremans, Ruben, Neven, Patrick, Bourne, Tom, Van Calster, Ben, Timmerman, Dirk, Lambrechts, Diether, and Vergote, Ignace

Published
2022
Full Text
View/download PDF

12. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Mahner, Sven, Reuss, Alexander, du Bois, Andreas, Grimm, Christoph, Marth, Christian, Berger, Regina, Concin, Nicole, Chang, Ting-Chang, Ochiai, Kazunori, Gebski, Val, Davis, Alison, Beale, Philip, Vergote, Ignace, Kridelka, Frédéric, Denys, Hannelore, Vandecaveye, Vincent, Candido dos Reis, Francisco Jose, Del Pilar Estevez Diz, Maria, Stuart, Gavin, MacKay, Helen, Carey, Mark, Cibula, David, Dundr (path), Pavel, Dorigo, Oliver, Berek, Jonathan, O'Donnell, Dearbhaile, Saadeh, Abu, Boere, Ingrid, Lok, Christianne, Coronado, Pluvio, Ottevanger, Nelleke, Tan, David SP, Ng, Joseph, Gonzalez Martin, Antonio, Oaknin, Ana, Poveda, Andres, Perez Fidalgo, Alejandro, Rauh-Hain, Alejandro, Lu, Karen, López-Zavala, Carlos, Gómez-García, Eva María, Ray-Coquard, Isabelle, Paoletti, Xavier, Kurtz, Jean-Emmanuel, Joly, Florence, Votan, Bénédicte, Bookman, Michael, Moore, Kathleen, Arend, Rebecca, Fujiwara, Keiichi, Fujiwara, Hiroyuki, Hasegawa, Kosei, Bruchim, Ilan, Tsoref, Dalia, Oda, Katsutoshi, Okamoto, Aikou, Enomoto, Takayuki, Michel, Dayana, Kim, Hee-Seung, Lee, Jung-Yun, Mukhopadhyay, Asima, Katsaros, Dionyssios, Colombo, Nicoletta, Pignata, Sandro, Lorusso, Domenica, Scambia, Giovanni, Kohn, Elise, Lee, Jung-Min, McNeish, Iain, Nicum, Shibani, Farrelly, Laura, Sehouli, Jalid, Keller, Maren, Braicu, Elena, Bjørge, Line, Mirza, Mansoor Raza, Auranen, Annika, Welch, Stephen, Oza, Amit M, Heinzelmann, Viola, Gourley, Charlie, Roxburgh, Patricia, Herrington, C Simon, Glasspool, Ros, Zang, Rongyu, Zhu, Jianqing, Gonzalez-Martin, Antonio, Kohn, Elise C, Berek, Jonathan S, Tan, David S P, Stuart, Gavin C E, and Bookman, Michael A

Published
2022
Full Text
View/download PDF

13. Uterine serous carcinoma

Author

Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Y.L., Morice, Philippe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Nout, Remi A., Lorusso, Domenica, Vaughan, Michelle M., Bini, Marta, Takano, Masashi, Provencher, Diane, Indini, Alice, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Candido dos Reis, Francisco J., Lopez, Salvatore, Mariani, Andrea, Leitao, Mario M., Jr, Raspagliesi, Francesco, Panici, Pieluigi Benedetti, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Scambia, Giovanni, Pignata, Sandro, and Monk, Bradley J.

Published
2021
Full Text
View/download PDF

14. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Author

Raspagliesi, Francesco, Melichar, Bohuslav, Gaba Garcia, Lydia, Jackson, Amanda, Henry, Stephanie, Kral, Zdenek, Harter, Philipp, De Giorgi, Ugo, Bjurberg, Maria, Gold, Michael, O'Malley, David, Honhon, Brigitte, Vulsteke, Christof, De Cuypere, Eveline, Denys, Hannelore, Baurain, Jean-Francois, Zamagni, Claudio, Tenney, Meaghan, Gordinier, Mary, Bradley, William, Schlumbrecht, Matthew, Spirtos, Nicola, Concin, Nicole, Mahner, Sven, Scambia, Giovanni, Leath, Charles, Farias-Eisner, Robin, Cohen, Joshua, Muller, Carolyn, Bhatia, Sumeet, Coleman, Robert L, Lorusso, Domenica, Gennigens, Christine, González-Martín, Antonio, Randall, Leslie, Cibula, David, Lund, Bente, Woelber, Linn, Pignata, Sandro, Forget, Frederic, Redondo, Andrés, Vindeløv, Signe Diness, Chen, Menghui, Harris, Jeffrey R, Smith, Margaret, Nicacio, Leonardo Viana, Teng, Melinda S L, Laenen, Annouschka, Rangwala, Reshma, Manso, Luis, Mirza, Mansoor, Monk, Bradley J, and Vergote, Ignace

Published
2021
Full Text
View/download PDF

15. Gene expression markers in peripheral blood and outcome in patients with platinum‐resistant ovarian cancer: A study of the European GANNET53 consortium.

Author

Obermayr, Eva, Mohr, Thomas, Schuster, Eva, Braicu, Elena Ioana, Taube, Eliane, Sehouli, Jalid, Vergote, Ignace, Pujade‐Lauraine, Eric, Ray‐Coquard, Isabelle, Harter, Philipp, Wimberger, Pauline, Joly‐Lobbedez, Florence, Mahner, Sven, Moll, Ute Martha, Concin, Nicole, and Zeillinger, Robert

Subjects
OVARIAN cancer, GENE expression, POLYMERASE chain reaction, DRUG administration, COMBINATION drug therapy
Abstract

Disease progression is a major problem in ovarian cancer. There are very few treatment options for patients with platinum‐resistant ovarian cancer (PROC), and therefore, these patients have a particularly poor prognosis. The aim of the present study was to identify markers for monitoring the response of 123 PROC patients enrolled in the Phase I/II GANNET53 clinical trial, which evaluated the efficacy of Ganetespib in combination with standard chemotherapy versus standard chemotherapy alone. In total, 474 blood samples were collected, comprising baseline samples taken before the first administration of the study drugs and serial samples taken during treatment until further disease progression (PD). After microfluidic enrichment, 27 gene transcripts were analyzed using quantitative polymerase chain reaction and their utility for disease monitoring was evaluated. At baseline, ERCC1 was associated with an increased risk of PD (hazard ratio [HR] 1.75, 95% confidence interval [CI]: 1.20–2.55; p = 0.005), while baseline CDH1 and ESR1 may have a risk‐reducing effect (CDH1 HR 0.66, 95% CI: 0.46–0.96; p = 0.024; ESR1 HR 0.58, 95% CI: 0.39–0.86; p = 0.002). ERCC1 was observed significantly more often (72.7% vs. 53.9%; p = 0.032) and ESR1 significantly less frequently (59.1% vs. 78.3%; p = 0.018) in blood samples taken at radiologically confirmed PD than at controlled disease. At any time during treatment, ERCC1‐presence and ESR1‐absence were associated with short PFS and with higher odds of PD within 6 months (odds ratio 12.77, 95% CI: 4.08–39.97; p < 0.001). Our study demonstrates the clinical relevance of ESR1 and ERCC1 and may encourage the analysis of liquid biopsy samples for the management of PROC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)‐induced phenotypes for platinum sensitivity and long‐term survival in ovarian cancer—A study from the OVCAD consortium.

Author

Fromhage, Gesa, Obermayr, Eva, Bednarz‐Knoll, Natalia, Van Gorp, Toon, Welsch, Eva, Polterauer, Stephan, Braicu, Elena Ioana, Mahner, Sven, Sehouli, Jalid, Vergote, Ignace, Concin, Nicole, Kurtz, Stefan, Steinbiss, Sascha, Torge, Antje, Zeillinger, Robert, Wölber, Linn, and Brandt, Burkhard

Subjects
EPIDERMAL growth factor receptors, OVARIAN epithelial cancer, OVARIAN cancer, CIRCULATING tumor DNA, RETROTRANSPOSONS, CHROMOSOMES
Abstract

We analyzed variations in the epidermal growth factor receptor (EGFR) gene and 5′‐upstream region to identify potential molecular predictors of treatment response in primary epithelial ovarian cancer. Tumor tissues collected during debulking surgery from the prospective multicenter OVCAD study were investigated. Copy number variations in the human endogenous retrovirus sequence human endogenous retrovirus K9 (HERVK9) and EGFR Exons 7 and 9, as well as repeat length and loss of heterozygosity of polymorphic CA‐SSR I and relative EGFR mRNA expression were determined quantitatively. At least one EGFR variation was observed in 94% of the patients. Among the 30 combinations of variations discovered, enhanced platinum sensitivity (n = 151) was found dominantly with HERVK9 haploidy and Exon 7 tetraploidy, overrepresented among patients with survival ≥120 months (24/29, p =.0212). EGFR overexpression (≥80 percentile) was significantly less likely in the responders (17% vs. 32%, p =.044). Multivariate Cox regression analysis, including age, FIGO stage, and grade, indicated that the patients' subgroup was prognostically significant for CA‐SSR I repeat length <18 CA for both alleles (HR 0.276, 95% confidence interval 0.109–0.655, p =.001). Although EGFR variations occur in ovarian cancer, the mRNA levels remain low compared to other EGFR‐mutated cancers. Notably, the inherited length of the CA‐SSR I repeat, HERVK9 haploidy, and Exon 7 tetraploidy conferred three times higher odds ratio to survive for more than 10 years under therapy. This may add value in guiding therapies if determined during follow‐up in circulating tumor cells or circulating tumor DNA and offers HERVK9 as a potential therapeutic target. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

Author

Concin, Nicole, Creutzberg, Carien L., Vergote, Ignace, Cibula, David, Mirza, Mansoor Raza, Marnitz, Simone, Ledermann, Jonathan A., Bosse, Tjalling, Chargari, Cyrus, Fagotti, Anna, Fotopoulou, Christina, González-Martín, Antonio, Lax, Sigurd F., Lorusso, Domenica, Marth, Christian, Morice, Philippe, Nout, Remi A., O’Donnell, Dearbhaile E., Querleu, Denis, Raspollini, Maria Rosaria, Sehouli, Jalid, Sturdza, Alina E., Taylor, Alexandra, Westermann, Anneke M., Wimberger, Pauline, Colombo, Nicoletta, Planchamp, François, and Matias-Guiu, Xavier

Published
2021
Full Text
View/download PDF

20. TP008/#1500 Trial in progress: phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer who responded to chemotherapy (ENGOT-EN21; GOG-3089)

Author

Concin, Nicole, primary, Giorgi, Ugo De, additional, Gorp, Toon Van, additional, Alexandre, Jérôme, additional, Lindemann, Kristina, additional, Marth, Christian, additional, Berger, Regina, additional, Cibula, David, additional, Quindos, Maria, additional, Bologna, Alessandra, additional, Korach, Jacob, additional, Papadimitriou, Christos, additional, Nicum, Shibani, additional, Collins, Dearbhaile, additional, Myers, Reg, additional, Rothbaum, Wayne, additional, Herzog, Thomas, additional, Monk, Bradley, additional, and Cloven, Noelle Gillette, additional

Published
2023
Full Text
View/download PDF

21. Gestational choriocarcinoma

Author

Bogani, Giorgio, primary, Ray-Coquard, Isabelle, additional, Mutch, David, additional, Vergote, Ignace, additional, Ramirez, Pedro T, additional, Prat, Jaime, additional, Concin, Nicole, additional, Ngoi, Natalie Yan Li, additional, Coleman, Robert L, additional, Enomoto, Takayuki, additional, Takehara, Kazuhiro, additional, Denys, Hannelore, additional, Lorusso, Domenica, additional, Takano, Masashi, additional, Sagae, Satoru, additional, Wimberger, Pauline, additional, Segev, Yakir, additional, Kim, Se Ik, additional, Kim, Jae-Weon, additional, Herrera, Fernanda, additional, Mariani, Andrea, additional, Brooks, Rebecca A, additional, Tan, David, additional, Paolini, Biagio, additional, Chiappa, Valentina, additional, Longo, Mariangela, additional, Raspagliesi, Francesco, additional, Benedetti Panici, Pierluigi, additional, Di Donato, Violante, additional, Caruso, Giuseppe, additional, Colombo, Nicoletta, additional, Pignata, Sandro, additional, Zannoni, Gianfranco, additional, Scambia, Giovanni, additional, and Monk, Bradley J, additional

Published
2023
Full Text
View/download PDF

22. #84 Trial in progress: a phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer (EC) who responded to chemotherapy (ENGOT-En21 and GOG-3089)

Author

Concin, Nicole, primary, Giorgi, Ugo De, additional, Gorp, Toon Van, additional, Alexandre, Jérôme, additional, Lindemann, Kristina, additional, Marth, Christian, additional, Berger, Regina, additional, Cibula, David, additional, Quindós, María, additional, Bologna, Alessandra, additional, Korach, Jacob, additional, Papadimitriou, Christos, additional, Nicum, Shibani, additional, Collins, Dearbhaile, additional, Myers, Reg, additional, Rothbaum, Wayne, additional, Herzog, Thomas J, additional, Monk, Bradley J, additional, and Cloven, Noelle Gillette, additional

Published
2023
Full Text
View/download PDF

23. #809 Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients– an international pooled analysis of three ESGO accredited centers

Author

Schwameis, Richard, primary, Fanfani, Francesco, additional, Ebner, Christoph, additional, Zimmermann, Naomi, additional, Peters, Inge, additional, Nero, Camilla, additional, Marth, Christian, additional, Ristl, Robin, additional, Leitner, Katharina, additional, Grimm, Christoph, additional, Oberndorfer, Felicitas, additional, Capasso, Ilaria, additional, Zeimet, Alain, additional, Polterauer, Stephan, additional, Scambia, Giovanni, additional, Fagotti, Anna, additional, and Concin, Nicole, additional

Published
2023
Full Text
View/download PDF

24. #450 Surgical management of malignant intestinal obstruction in patients with ovarian cancer – ten-year experience of a tertiary gynecologic oncology department

Author

Zdanyte, Kristina, primary, Harter, Philipp, additional, Hinrichs, Jacob, additional, Moubarak, Malak, additional, Traut, Alexander, additional, Welz, Julia, additional, Voswinkel, Martje, additional, Schneider, Stephanie, additional, Vrentas, Vasileios, additional, Concin, Nicole, additional, Walz, Martin, additional, and Heitz, Florian, additional

Published
2023
Full Text
View/download PDF

25. #644 Surgical management of FIGO stage IV epithelial ovarian cancer versus FIGO stage IIIC: the real-world experience from KEM

Author

Tsibulak, Irina, primary, Moubarak, Malak, additional, Schneider, Stephanie, additional, Traut, Alexander, additional, Welz, Julia, additional, Concin, Nicole, additional, Bommert, Mareike, additional, Vrentas, Vasileios, additional, Zdanyte, Kristina, additional, Bennefeld, Luisa, additional, Kaiser, Sabrina, additional, Westermann, Timo, additional, Heitz, Florian, additional, and Harter, Philipp, additional

Published
2023
Full Text
View/download PDF

28. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Author

de Bono, Johann S, Concin, Nicole, Hong, David S, Thistlethwaite, Fiona C, Machiels, Jean-Pascal, Arkenau, Hendrik-Tobias, Plummer, Ruth, Jones, Robert Hugh, Nielsen, Dorte, Windfeld, Kristian, Ghatta, Srinivas, Slomovitz, Brian M, Spicer, James F, Yachnin, Jeffrey, Ang, Joo Ern, Mau-Sørensen, Paul Morten, Forster, Martin David, Collins, Dearbhaile, Dean, Emma, Rangwala, Reshma A, and Lassen, Ulrik

Published
2019
Full Text
View/download PDF

29. Response to: Correspondence on 'ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors' by Thomassin-Nagarra et al

Author

Timmerman, Dirk, Cibula, David, Planchamp, François, Bourne, Tom, Landolfo, Chiara, Testa, Antonia Carla, du Bois, Andreas, Chiva, Luis, Concin, Nicole, fisherova, Daniela, Froyman, Wouter, Lemley, Birthe, Loft, Annika, Mereu, Liliana, Morice, Philippe, Querleu, Denis, Vergote, Ignace, Vandecaveye, Vincent, Scambia, Giovanni, and Fotopoulou, Christina

Published
2021
Full Text
View/download PDF

30. The genetic landscape of 87 ovarian germ cell tumors

Author

Van Nieuwenhuysen, Els, Busschaert, Pieter, Neven, Patrick, Han, Sileny N., Moerman, Philippe, Liontos, Michalis, Papaspirou, Maria, Kupryjanczyk, Jolanta, Hogdall, Claus, Hogdall, Estrid, Oaknin, Ana, Garcia, Angel, Mahner, Sven, Trillsch, Fabian, Cibula, David, Heitz, Florian, Concin, Nicole, Speiser, Paul, Salvesen, Helga, Sehouli, Jalid, Lambrechts, Diether, and Vergote, Ignace

Published
2018
Full Text
View/download PDF

32. Response: FIGO staging of endometrial cancer 2023.

Author

Concin, Nicole, Matias‐Guiu, Xavier, Fotopoulou, Christina, Creutzberg, Carien, Mutch, David, Gaffney, David, Lindemann, Kristina, Kehoe, Sean, and Berek, Jonathan S.

Subjects
*ENDOMETRIAL cancer, *TUMOR classification, *SCIENTIFIC knowledge, *PROGNOSIS, *CANCER patients
Abstract

The article discusses the new 2023 FIGO staging system for endometrial cancer, which takes into account advancements in scientific knowledge and the heterogeneity of tumors. The system aims to improve prognostic precision and individualize treatment approaches by integrating biomarkers and molecular parameters. Several validation studies have demonstrated the higher prognostic value of the new staging system compared to the previous 2009 system. The article also addresses concerns about upstaging and the impact of molecular classification, as well as the need for global resource availability and cost-effective analysis. Overall, the new staging system is seen as a step forward in improving the care and treatment of women with endometrial cancer. [Extracted from the article]

Published
2024
Full Text
View/download PDF

33. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

Author

Timmerman, Dirk, Planchamp, François, Bourne, Tom, Landolfo, Chiara, du Bois, Andreas, Chiva, Luis, Cibula, David, Concin, Nicole, Fischerova, Daniela, Froyman, Wouter, Madueño, Guillermo Gallardo, Lemley, Birthe, Loft, Annika, Mereu, Liliana, Morice, Philippe, Querleu, Denis, Testa, Antonia Carla, Vergote, Ignace, Vandecaveye, Vincent, Scambia, Giovanni, and Fotopoulou, Christina

Published
2021
Full Text
View/download PDF

35. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

Author

Guan, Jun, Darb-Esfahani, Silvia, Richter, Rolf, Taube, Eliane T., Ruscito, Ilary, Mahner, Sven, Woelber, Linn, Prieske, Katharina, Concin, Nicole, Vergote, Ignace, Van Nieuwenhuysen, Els, Achimas-Cadariu, Patriciu, Glajzer, Joanna, Woopen, Hannah, Stanske, Mandy, Kulbe, Hagen, Denkert, Carsten, Sehouli, Jalid, and Braicu, Elena Ioana

Published
2019
Full Text
View/download PDF

36. Prognostic factors in patients with uterine sarcoma: the SARCUT study

Author

Zapardiel, Ignacio, primary, Gracia Segovia, Myriam, additional, Macuks, Ronalds, additional, Mancari, Rosanna, additional, Achimas-Cadariu, Patriciu, additional, Corrado, Giacomo, additional, Bartusevicius, Arnoldas, additional, Sukhin, Vladyslav, additional, Muruzabal, Juan C, additional, Coronado Martín, Pluvio J, additional, Gardella, Barbara, additional, Piek, Jurgen M, additional, Concin, Nicole, additional, Arab, Clemente, additional, Papatheodorou, Dimitrios, additional, Polterauer, Stephan, additional, Iacoponi, Sara, additional, Nieto, Teresa, additional, Lopez-Sanclemente, Martha C, additional, Trukhan, Hanna, additional, Gil, Maria M, additional, Bakinovskaya, Irina, additional, Dalamanava, Alena, additional, Cucurull, Marc, additional, Rovski, Dzmitry, additional, Baquedano, Laura, additional, Chiva, Luis, additional, Mardas, Marcin, additional, Mavrichev, Siarhei Anatolievich, additional, Klat, Jaroslav, additional, Lopez de la Manzanara, Carlos A, additional, and Yildirim, Yusuf, additional

Published
2023
Full Text
View/download PDF

37. Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients

Author

Imterat, Majdi, primary, Harter, Philipp, additional, Rhiem, Kerstin, additional, Heitz, Florian, additional, Schneider, Stephanie, additional, Concin, Nicole, additional, Moubarak, Malak, additional, Welz, Julia, additional, Vrentas, Vasileios, additional, Traut, Alexander, additional, Hahnen, Eric, additional, Schmutzler, Rita, additional, du Bois, Andreas, additional, and Ataseven, Beyhan, additional

Published
2023
Full Text
View/download PDF

38. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

Author

Leroy, Bernard, primary, Ballinger, Mandy L., primary, Baran-Marszak, Fanny, primary, Bond, Gareth L., primary, Braithwaite, Antony, primary, Concin, Nicole, primary, Donehower, Lawrence A., primary, El-Deiry, Wafik S., primary, Fenaux, Pierre, primary, Gaidano, Gianluca, primary, Langerød, Anita, primary, Hellstrom-Lindberg, Eva, primary, Iggo, Richard, primary, Lehmann-Che, Jacqueline, primary, Mai, Phuong L., primary, Malkin, David, primary, Moll, Ute M., primary, Myers, Jeffrey N., primary, Nichols, Kim E., primary, Pospisilova, Sarka, primary, Ashton-Prolla, Patricia, primary, Rossi, Davide, primary, Savage, Sharon A., primary, Strong, Louise C., primary, Tonin, Patricia N., primary, Zeillinger, Robert, primary, Zenz, Thorsten, primary, Fraumeni, Joseph F., primary, Taschner, Peter E.M., primary, Hainaut, Pierre, primary, and Soussi, Thierry, primary

Published
2023
Full Text
View/download PDF

39. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

Author

Leroy, Bernard, primary, Ballinger, Mandy L., primary, Baran-Marszak, Fanny, primary, Bond, Gareth L., primary, Braithwaite, Antony, primary, Concin, Nicole, primary, Donehower, Lawrence A., primary, El-Deiry, Wafik S., primary, Fenaux, Pierre, primary, Gaidano, Gianluca, primary, Langerød, Anita, primary, Hellstrom-Lindberg, Eva, primary, Iggo, Richard, primary, Lehmann-Che, Jacqueline, primary, Mai, Phuong L., primary, Malkin, David, primary, Moll, Ute M., primary, Myers, Jeffrey N., primary, Nichols, Kim E., primary, Pospisilova, Sarka, primary, Ashton-Prolla, Patricia, primary, Rossi, Davide, primary, Savage, Sharon A., primary, Strong, Louise C., primary, Tonin, Patricia N., primary, Zeillinger, Robert, primary, Zenz, Thorsten, primary, Fraumeni, Joseph F., primary, Taschner, Peter E.M., primary, Hainaut, Pierre, primary, and Soussi, Thierry, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Author

Hong, David S., primary, Concin, Nicole, primary, Vergote, Ignace, primary, de Bono, Johann S., primary, Slomovitz, Brian M., primary, Drew, Yvette, primary, Arkenau, Hendrik-Tobias, primary, Machiels, Jean-Pascal, primary, Spicer, James F., primary, Jones, Robert, primary, Forster, Martin D., primary, Cornez, Nathalie, primary, Gennigens, Christine, primary, Johnson, Melissa L., primary, Thistlethwaite, Fiona C., primary, Rangwala, Reshma A., primary, Ghatta, Srinivas, primary, Windfeld, Kristian, primary, Harris, Jeffrey R., primary, Lassen, Ulrik Niels, primary, and Coleman, Robert L., primary

Published
2023
Full Text
View/download PDF

41. Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Author

Hong, David S., primary, Concin, Nicole, primary, Vergote, Ignace, primary, de Bono, Johann S., primary, Slomovitz, Brian M., primary, Drew, Yvette, primary, Arkenau, Hendrik-Tobias, primary, Machiels, Jean-Pascal, primary, Spicer, James F., primary, Jones, Robert, primary, Forster, Martin D., primary, Cornez, Nathalie, primary, Gennigens, Christine, primary, Johnson, Melissa L., primary, Thistlethwaite, Fiona C., primary, Rangwala, Reshma A., primary, Ghatta, Srinivas, primary, Windfeld, Kristian, primary, Harris, Jeffrey R., primary, Lassen, Ulrik Niels, primary, and Coleman, Robert L., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 1 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

Author

Reimer, Daniel, primary, Hubalek, Michael, primary, Riedle, Svenja, primary, Skvortsov, Sergej, primary, Erdel, Martin, primary, Concin, Nicole, primary, Fiegl, Heidi, primary, Müller-Holzner, Elisabeth, primary, Marth, Christian, primary, Illmensee, Karl, primary, Altevogt, Peter, primary, and Zeimet, Alain G., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 2 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

Author

Reimer, Daniel, primary, Hubalek, Michael, primary, Riedle, Svenja, primary, Skvortsov, Sergej, primary, Erdel, Martin, primary, Concin, Nicole, primary, Fiegl, Heidi, primary, Müller-Holzner, Elisabeth, primary, Marth, Christian, primary, Illmensee, Karl, primary, Altevogt, Peter, primary, and Zeimet, Alain G., primary

Published
2023
Full Text
View/download PDF

45. Data from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer

Author

Strasak, Alexander M., primary, Goebel, Georg, primary, Concin, Hans, primary, Pfeiffer, Ruth M., primary, Brant, Larry J., primary, Nagel, Gabriele, primary, Oberaigner, Willi, primary, Concin, Nicole, primary, Diem, Günter, primary, Ruttmann, Elfriede, primary, Gruber-Moesenbacher, Ulrike, primary, Offner, Felix, primary, Pompella, Alfonso, primary, Pfeiffer, Karl P., primary, and Ulmer, Hanno, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 1 from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer

Author

Strasak, Alexander M., primary, Goebel, Georg, primary, Concin, Hans, primary, Pfeiffer, Ruth M., primary, Brant, Larry J., primary, Nagel, Gabriele, primary, Oberaigner, Willi, primary, Concin, Nicole, primary, Diem, Günter, primary, Ruttmann, Elfriede, primary, Gruber-Moesenbacher, Ulrike, primary, Offner, Felix, primary, Pompella, Alfonso, primary, Pfeiffer, Karl P., primary, and Ulmer, Hanno, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

Author

Reimer, Daniel, primary, Hubalek, Michael, primary, Riedle, Svenja, primary, Skvortsov, Sergej, primary, Erdel, Martin, primary, Concin, Nicole, primary, Fiegl, Heidi, primary, Müller-Holzner, Elisabeth, primary, Marth, Christian, primary, Illmensee, Karl, primary, Altevogt, Peter, primary, and Zeimet, Alain G., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Tables 1-3, Figure Legends 1-3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

Author

Reimer, Daniel, primary, Hubalek, Michael, primary, Riedle, Svenja, primary, Skvortsov, Sergej, primary, Erdel, Martin, primary, Concin, Nicole, primary, Fiegl, Heidi, primary, Müller-Holzner, Elisabeth, primary, Marth, Christian, primary, Illmensee, Karl, primary, Altevogt, Peter, primary, and Zeimet, Alain G., primary

Published
2023
Full Text
View/download PDF

49. Impact of Hospital Case Volume on Uterine Sarcoma Prognosis: SARCUT Study Subanalysis.

Author

Gorostidi, Mikel, Yildirim, Yusuf, Macuks, Ronalds, Mancari, Rosanna, Achimas-Cadariu, Patriciu, Ibañez, Eduardo, Corrado, Giacomo, Bartusevicius, Arnoldas, Sukhina, Olena, Zapardiel, Ignacio, on behalf of SARCUT Study Group, Martínez, María Silvana Aniorte, Eblen, Clemente Arab, Bakinovskaya, Irina, Baquedano, Laura, Bhugwandass, Celine, Chiva, Luis, Concin, Nicole, Martín, Pluvio J. Coronado, and López, Laura Cusiné

Abstract

Background: High-complexity and low-prevalence procedures benefit from treatment by referral centers. The volume of cases necessary to maintain high training in the treatment of gynecologic sarcoma is currently unknown. This study aimed to determine differences in survival and recurrence as a function of the volume of patients treated per center. Methods: The multicentric cross-sectional SARComa of the Uterus (SARCUT) study retrospectively collected cases of uterine sarcomas from 44 centers in Europe from January 2001 to December 2007. The survival of patients treated in high case-volume (HighCV) centers was compared with the survival of patients treated in low case-volume (LowCV) centers. Results: The study enrolled 966 patients: 753 in the LowCV group and 213 in the HighCV. Overall survival (OS) was 117 months, and cancer-specific survival (CSS) was 126 months. The difference was significant (respectively p = 0.0003 and 0.0004, log rank). After adjustment for other confounding factors, the remaining significant factors were age (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.03–1.05), histology (HR, 1.19; 95% CI, 1.06–1.34), extrauterine involvement (HR, 1.61; 95% CI, 1.24–2.10) and persistent disease after treatment (HR, 3.22; 95% CI, 2.49–4.18). The cytoreduction performed was significantly associated with the CSS and OS in both groups. The log rank for surgical cytoreduction was a p value lower than 0.0001 for OS, lower than 0.0001 for the LowCV centers, and 0.0032 for the HighCV centers. Conclusions: The prognosis for patients with uterine sarcoma is directly related to complete tumor cytoreduction, histologic type, and FIGO stage, with significant differences between low and high case-volume centers. Patients with uterine sarcomas should be centralized in HighCV centers to improve their oncologic outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. FIGO staging of endometrial cancer: 2023.

Author

Berek, Jonathan S., Matias-Guiu, Xavier, Creutzberg, Carien, Fotopoulou, Christina, Gaffney, David, Kehoe, Sean, Lindemann, Kristina, Mutch, David, and Concin, Nicole

Subjects
MICROMETASTASIS, ENDOMETRIAL cancer, TUMOR classification, LYMPHATIC metastasis, CANCER patients
Abstract

Introduction: Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies. Methods: The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system. Results: Based on the existing evidence, the substages were defined as follows: S tage I (IA1): non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion. S tage II (IIA): non-aggressive histological types that infiltrate the cervical stroma; (IIB) nonaggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion. S tage III (IIIA): differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis. S tage IV (IVA): locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis. The performance of complete molecular classification ( POLEmut, MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of "m" for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or POLEmut status in Stages I and II, this results in upstaging or downstaging of the disease (IICmp53abn or IAmPOLEmut). Summary: The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results